Invesco Ltd. Raises Stock Position in Sanofi (NASDAQ:SNY)

Invesco Ltd. grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,059,283 shares of the company's stock after purchasing an additional 408,752 shares during the quarter. Invesco Ltd. owned approximately 0.48% of Sanofi worth $581,619,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after purchasing an additional 33,105 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Sanofi by 1.0% in the 3rd quarter. HighTower Advisors LLC now owns 88,100 shares of the company's stock worth $5,081,000 after buying an additional 848 shares during the last quarter. IHT Wealth Management LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $227,000. State Street Corp grew its holdings in shares of Sanofi by 0.5% in the third quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after acquiring an additional 264 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its position in shares of Sanofi by 47.7% during the third quarter. EP Wealth Advisors LLC now owns 7,895 shares of the company's stock valued at $455,000 after acquiring an additional 2,548 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of NASDAQ SNY traded up $1.84 during trading on Friday, reaching $51.50. 3,191,009 shares of the stock traded hands, compared to its average volume of 2,326,973. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market capitalization of $130.10 billion, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a 50-day moving average of $54.97 and a 200-day moving average of $52.35.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.